{"organizations": [], "uuid": "21afd5cb8473b298aecead3e9124b5769b96a051", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-apellis-pharmaceuticals-provides-u/brief-apellis-pharmaceuticals-provides-update-on-phase-1b-open-label-study-of-apl-2-in-pnh-patients-not-previously-treated-with-eculizumab-idUSASC09VYA", "country": "US", "domain_rank": 408, "title": "BRIEF-Apellis Pharmaceuticals Provides Update On Phase 1B Open Label Study Of APL-2 In Pnh Patients Not Previously Treated With Eculizumab", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-16T16:35:00.000+03:00", "replies_count": 0, "uuid": "21afd5cb8473b298aecead3e9124b5769b96a051"}, "author": "", "url": "https://www.reuters.com/article/brief-apellis-pharmaceuticals-provides-u/brief-apellis-pharmaceuticals-provides-update-on-phase-1b-open-label-study-of-apl-2-in-pnh-patients-not-previously-treated-with-eculizumab-idUSASC09VYA", "ord_in_thread": 0, "title": "BRIEF-Apellis Pharmaceuticals Provides Update On Phase 1B Open Label Study Of APL-2 In Pnh Patients Not Previously Treated With Eculizumab", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "eculizumab reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "apellis pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Market News April 16, 2018 / 1:36 PM / Updated 7 minutes ago BRIEF-Apellis Pharmaceuticals Provides Update On Phase 1B Open Label Study Of APL-2 In Pnh Patients Not Previously Treated With Eculizumab Reuters Staff 1 Min Read \nApril 16 (Reuters) - Apellis Pharmaceuticals Inc: \n* APELLIS PHARMACEUTICALS PROVIDES UPDATE ON PHASE 1B OPEN LABEL STUDY OF APL-2 IN PNH PATIENTS NOT PREVIOUSLY TREATED WITH ECULIZUMAB \n* APELLIS PHARMACEUTICALS INC - TO DATE, APL-2 HAS GENERALLY BEEN WELL-TOLERATED IN PATIENTS \n* APELLIS PHARMACEUTICALS INC - EXPECTS TO REPORTING FURTHER UPDATES TO ONGOING PADDOCK TRIAL IN JUNE \n* APELLIS - IN H2 2018, PLANS TO INITIATE A PHASE 3 TRIAL IN 70 PATIENTS WITH PNH VERSUS TREATMENT WITH APL-2 MONOTHERAPY TO TREATMENT WITH ECULIZUMAB Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-16T16:35:00.000+03:00", "crawled": "2018-04-16T16:53:20.004+03:00", "highlightTitle": ""}